Yesterday, May 23, 2016, 103 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $126.00 to $24,869,360.00.

Highlighted Stocks Traded by Insiders:

Supreme Industries (STS) - FREE Research Report

Barrett Peter D, who is Director at Supreme Industries, sold 2,300 shares at $13.00 on May 23, 2016. Following this transaction, the Director owned 21,052 shares meaning that the stake was reduced by 9.85% with the 2,300-share transaction.

The shares most recently traded at $11.97, down $1.03, or 8.6% since the insider transaction. Historical insider transactions for Supreme Industries go as follows:

  • 4-Week # shares bought: 1,779
  • 4-Week # shares sold: 52,755
  • 12-Week # shares bought: 1,779
  • 12-Week # shares sold: 54,255
  • 24-Week # shares bought: 1,779
  • 24-Week # shares sold: 54,708

The average volume for Supreme Industries has been 94,800 shares per day over the past 30 days. Supreme Industries has a market cap of $220.2 million and is part of the consumer goods sector and automotive industry. Shares are up 72.99% year-to-date as of the close of trading on Monday.

Supreme Industries, Inc., through its subsidiary, Supreme Corporation, manufactures and sells truck bodies, trolleys, and specialty vehicles in the United States. It operates through two segments, Specialized Commercial Vehicles and Fiberglass Products. The stock currently has a dividend yield of 0.93%. The company has a P/E ratio of 14.9. Currently, there are no analysts who rate Supreme Industries a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STS - FREE

TheStreet Quant Ratings

rates Supreme Industries as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Supreme Industries Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Red Robin Gourmet Burgers (RRGB) - FREE Research Report

Brown Stuart B, who is Chief Financial Officer at Red Robin Gourmet Burgers, bought 500 shares at $48.44 on May 23, 2016. Following this transaction, the Chief Financial Officer owned 21,636 shares meaning that the stake was boosted by 2.37% with the 500-share transaction.

The shares most recently traded at $49.18, up $0.74, or 1.5% since the insider transaction. Historical insider transactions for Red Robin Gourmet Burgers go as follows:

  • 4-Week # shares bought: 600
  • 4-Week # shares sold: 890
  • 12-Week # shares bought: 600
  • 12-Week # shares sold: 890
  • 24-Week # shares bought: 600
  • 24-Week # shares sold: 890

The average volume for Red Robin Gourmet Burgers has been 288,100 shares per day over the past 30 days. Red Robin Gourmet Burgers has a market cap of $660.4 million and is part of the services sector and leisure industry. Shares are down 22.66% year-to-date as of the close of trading on Monday.

TST Recommends

Red Robin Gourmet Burgers, Inc., together with its subsidiaries, develops, operates, and franchises casual-dining and fast-casual restaurants in the United States and Canada. As of May 9, 2016, it had approximately 530 Red Robin restaurants, including those operating under franchise agreements. The company has a P/E ratio of 15.0. Currently, there are 5 analysts who rate Red Robin Gourmet Burgers a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RRGB - FREE

TheStreet Quant Ratings

rates Red Robin Gourmet Burgers as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Red Robin Gourmet Burgers Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 1,050 shares at $10.18 on May 23, 2016. Following this transaction, the Senior V.P., Research owned 456,112 shares meaning that the stake was reduced by 0.23% with the 1,050-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 973 shares at $10.18 on May 23, 2016. Following this transaction, the Svp, Cfo owned 133,099 shares meaning that the stake was reduced by 0.73% with the 973-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 784 shares at $10.20 on May 23, 2016. Following this transaction, the Senior VP, Pharmaceutical Scie owned 157,253 shares meaning that the stake was reduced by 0.5% with the 784-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 1,000 shares at $10.40 on May 23, 2016. Following this transaction, the SVP & General Counsel owned 183,982 shares meaning that the stake was reduced by 0.54% with the 1,000-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 1,092 shares at $10.18 on May 23, 2016. Following this transaction, the Senior VP, Development and Chi owned 157,563 shares meaning that the stake was reduced by 0.69% with the 1,092-share transaction.

The shares most recently traded at $10.77, up $0.59, or 5.48% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,843
  • 12-Week # shares sold: 2,843
  • 24-Week # shares sold: 30,231

The average volume for Momenta Pharmaceuticals has been 598,000 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $723.5 million and is part of the health care sector and drugs industry. Shares are down 29.04% year-to-date as of the close of trading on Monday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 5 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings

rates Momenta Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally disappointing historical performance in the stock itself. Get the full

Momenta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.